重组人白介素-29-Fc融合蛋白在HEK-293F细胞中的表达及体外抗肿瘤活性分析  

Expression of recombinant human interleukin-29-Fc fusion protein in HEK293F cells and analysis of its anti-tumor activity in vitro

作　　者：闫甲丽 左群 祁芳冰 刘明杨 刘建伟 李素贞 柳森 王健 YAN Jiali;ZUO Qun;QI Fangbing;LIU Mingyang;LIU Jianwei;LI Suzhen;LIU Sen;WANG Jian(The Fourth Laboratory of National Vaccine and Serum Institute,Beijing 101111,China)

机构地区：[1]国药中生生物技术研究院有限公司第四研究室,北京101111

出　　处：《中国生物制品学杂志》2023年第5期559-565,共7页Chinese Journal of Biologicals

基　　金：国家科技重大专项(2010ZX09401-407)。

摘　　要：目的在人胚肾293F(human embryonic kidney 293F,HEK-293F)细胞中表达重组人白介素-29-Fc(recombinant human interleukin-29-Fc,rhIL-29-Fc)融合蛋白,并分析其体外抗肿瘤活性。方法构建重组UCOE-IL-29-Fc表达质粒,瞬时转染HEK-293F细胞,经表达、纯化后获得rhIL-29-Fc融合蛋白,经SDS-PAGE和Western blot进行鉴定;将rhIL-29和rhIL-29-Fc蛋白分别经左耳皮下免疫雌性日本大耳白兔,每组2只,0.5 mg/只,右耳静脉采血,分离血清,ELISA法检测半衰期;CCK-8试验检测rhIL-29-Fc蛋白对人结肠癌HT-29、人结肠癌HCT-116、人Burkkit淋巴瘤Daudi、人非小细胞肺癌NCI-H1975、人小细胞肺癌NCI-H209、人食管癌EC109和人胰腺癌PANC-1细胞的体外抗增殖效果,并计算半数抑制浓度(inhibitory concentration 50,IC_(50))。结果重组表达质粒UCOE-IL-29-Fc经双酶切及测序鉴定证明构建正确,瞬时转染HEK-293细胞6 d后,收获培养上清,经纯化获得的rhIL-29-Fc融合蛋白相对分子质量与预期相符,蛋白浓度为1.5 mg/mL,纯度为93%,可与小鼠抗人IL-29抗体特异性结合。rhIL-29-Fc蛋白半衰期为25 h,对7种肿瘤细胞显示出不同程度的增殖抑制效应,对不同细胞的IC50也不同。结论利用HEK-293F细胞成功表达rhIL-29-Fc融合蛋白,该融合蛋白半衰期比rhIL-29延长了20 h。根据7种肿瘤细胞显示出不同程度的体外增殖抑制效应和IC50测定结果,发现rhIL-29-Fc融合蛋白的抗肿瘤活性高于rhIL-29。该研究为IL-29蛋白治疗肿瘤的开发奠定了基础。Objective To express recombinant human interleukin-29-Fc(rhIL-29-Fc) fusion protein in human embryonic kidney 293-F(HEK293F) cells and analyze its anti-tumor activity in vitro.Methods The recombinant expression plasmid UCOE-IL-29-Fc was constructed and transiently transfected into HEK-293F cells.After expression and purification,rhIL-29-Fc fusion protein was obtained and identified by SDS-PAGE and Western blot;Female Japanese white rabbits were immunized with rhIL-29 and rhIL-29-Fc protein subcutaneously in the left ear respectively,2 rabbits in each group,0.5 mg per rabbit.Blood samples were collected from the vein of right ear,and the serum was separated.The half-life was measured by ELISA and the anti-proliferation effect of rhIL-29-Fc protein on human colon cancer HT-29,human colon cancer HCT-116,human Burkkit lymphoma Daudi,human non-small cell lung cancer NCI-H1975,human small cell lung cancer NCI-H209,human esophageal cancer EC109 and human pancreatic cancer PANC-1 cells in vitro was detected by CCK-8 assay,and the inhibitory concentration 50(IC_(50)) was calculated.Results The recombinant expression plasmid UCOE-IL-29-Fc was constructed correctly as identified by double digestion and sequencing.After transient transfection into HEK-293 cells for 6 d,the culture supernatant was harvested.The relative molecular mass of the purified rhIL-29-Fc fusion protein was consistent with the expectation.The protein showed a specific binding reaction with mouse anti-human IL-29 monoclonal antibody with a concentration of 1.5 mg/ml and a purity of 93%.RhIL-29-Fc protein had a half-life of 25 h and showed different inhibitory effects on the proliferation of 7 kinds of tumor cells,and the IC_(50) on different cells was also different.Conclusion The rhIL-29-Fc fusion protein was successfully expressed in HEK-293F cells,and the half-life of the fusion protein was 20 h longer than that of rhIL-29.According to the different anti-tumor proliferation activity in vitro and IC_(50) results on 7 kinds of tumor cells,it was found t

关 键 词：重组人白介素-29 FC融合蛋白 半衰期 抗肿瘤活性 半数抑制浓度 

分 类 号：Q789[生物学—分子生物学]